JP6677634B2 - ＳＣ−β細胞及び組成物並びにその生成方法 - Google Patents

ＳＣ−β細胞及び組成物並びにその生成方法 Download PDF

Info

Publication number
JP6677634B2
JP6677634B2 JP2016519628A JP2016519628A JP6677634B2 JP 6677634 B2 JP6677634 B2 JP 6677634B2 JP 2016519628 A JP2016519628 A JP 2016519628A JP 2016519628 A JP2016519628 A JP 2016519628A JP 6677634 B2 JP6677634 B2 JP 6677634B2
Authority
JP
Japan
Prior art keywords
cells
cell
positive
item
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016519628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531087A5 (enExample
JP2016531087A (ja
Inventor
クイン ピー． ピーターソン，
クイン ピー． ピーターソン，
フェリシア ジェイ． パリュウカ，
フェリシア ジェイ． パリュウカ，
ダグラス エー． メルトン，
ダグラス エー． メルトン，
ジェフリー アール． ミルマン，
ジェフリー アール． ミルマン，
マイケル サリス シーゲル，
マイケル サリス シーゲル，
マッズ ギュルトラー，
マッズ ギュルトラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2016531087A publication Critical patent/JP2016531087A/ja
Publication of JP2016531087A5 publication Critical patent/JP2016531087A5/ja
Priority to JP2020044320A priority Critical patent/JP7354026B2/ja
Application granted granted Critical
Publication of JP6677634B2 publication Critical patent/JP6677634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016519628A 2013-06-11 2014-06-11 ＳＣ−β細胞及び組成物並びにその生成方法 Active JP6677634B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020044320A JP7354026B2 (ja) 2013-06-11 2020-03-13 ＳＣ－β細胞及び組成物並びにその生成方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361833898P 2013-06-11 2013-06-11
US61/833,898 2013-06-11
US201461972212P 2014-03-28 2014-03-28
US61/972,212 2014-03-28
PCT/US2014/041992 WO2014201167A1 (en) 2013-06-11 2014-06-11 SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020044320A Division JP7354026B2 (ja) 2013-06-11 2020-03-13 ＳＣ－β細胞及び組成物並びにその生成方法

Publications (3)

Publication Number Publication Date
JP2016531087A JP2016531087A (ja) 2016-10-06
JP2016531087A5 JP2016531087A5 (enExample) 2017-07-13
JP6677634B2 true JP6677634B2 (ja) 2020-04-08

Family

ID=52022750

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2016519628A Active JP6677634B2 (ja) 2013-06-11 2014-06-11 ＳＣ−β細胞及び組成物並びにその生成方法
JP2016519627A Active JP6514689B2 (ja) 2013-06-11 2014-06-11 ＳＣ−β細胞及び組成物並びにその生成方法
JP2019076519A Active JP6893527B2 (ja) 2013-06-11 2019-04-12 ＳＣ−β細胞及び組成物並びにその生成方法
JP2020044320A Active JP7354026B2 (ja) 2013-06-11 2020-03-13 ＳＣ－β細胞及び組成物並びにその生成方法
JP2021091996A Pending JP2021121223A (ja) 2013-06-11 2021-06-01 ＳＣ−β細胞及び組成物並びにその生成方法
JP2023070217A Active JP7766641B2 (ja) 2013-06-11 2023-04-21 ＳＣ－β細胞及び組成物並びにその生成方法
JP2024017609A Pending JP2024054254A (ja) 2013-06-11 2024-02-08 ＳＣ－β細胞及び組成物並びにその生成方法
JP2025009884A Pending JP2025063288A (ja) 2013-06-11 2025-01-23 ＳＣ－β細胞及び組成物並びにその生成方法
JP2026012730A Pending JP2026082908A (ja) 2013-06-11 2026-01-29 ＳＣ－β細胞及び組成物並びにその生成方法

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2016519627A Active JP6514689B2 (ja) 2013-06-11 2014-06-11 ＳＣ−β細胞及び組成物並びにその生成方法
JP2019076519A Active JP6893527B2 (ja) 2013-06-11 2019-04-12 ＳＣ−β細胞及び組成物並びにその生成方法
JP2020044320A Active JP7354026B2 (ja) 2013-06-11 2020-03-13 ＳＣ－β細胞及び組成物並びにその生成方法
JP2021091996A Pending JP2021121223A (ja) 2013-06-11 2021-06-01 ＳＣ−β細胞及び組成物並びにその生成方法
JP2023070217A Active JP7766641B2 (ja) 2013-06-11 2023-04-21 ＳＣ－β細胞及び組成物並びにその生成方法
JP2024017609A Pending JP2024054254A (ja) 2013-06-11 2024-02-08 ＳＣ－β細胞及び組成物並びにその生成方法
JP2025009884A Pending JP2025063288A (ja) 2013-06-11 2025-01-23 ＳＣ－β細胞及び組成物並びにその生成方法
JP2026012730A Pending JP2026082908A (ja) 2013-06-11 2026-01-29 ＳＣ－β細胞及び組成物並びにその生成方法

Country Status (17)

Country Link
US (16) US20170029778A1 (enExample)
EP (4) EP3008170A4 (enExample)
JP (9) JP6677634B2 (enExample)
KR (12) KR102341674B1 (enExample)
CN (6) CN120796168A (enExample)
AU (7) AU2014278178B2 (enExample)
BR (2) BR112015030972A8 (enExample)
CA (3) CA3311831A1 (enExample)
DE (2) DE112014002780B4 (enExample)
DK (1) DK3008168T3 (enExample)
GB (3) GB2557508B (enExample)
HK (1) HK1257187B (enExample)
MX (2) MX2015017103A (enExample)
PH (1) PH12015502767A1 (enExample)
RU (2) RU2016100219A (enExample)
SG (3) SG11201510176VA (enExample)
WO (2) WO2015002724A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093654A (ja) * 2013-06-11 2023-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＳＣ－β細胞及び組成物並びにその生成方法

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
MX2015008578A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
EP2983694B1 (en) * 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
SG11201609473XA (en) 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100921A1 (en) * 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100857A1 (en) * 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
US10975355B2 (en) 2015-04-23 2021-04-13 The Regents Of The University Of California Controlled induction of human pancreatic progenitors produces functional beta-like cells
ES2840076T3 (es) * 2015-04-24 2021-07-06 Univ Copenhagen Aislamiento de células progenitoras pancreáticas bona fide
PT3285572T (pt) * 2015-04-24 2021-03-04 Univ Copenhagen Método para a produção de células produtoras de insulina
US11332716B2 (en) 2015-07-27 2022-05-17 The Regents Of The University Of California Methods and compositions for producing pancreatic beta cells
US11499140B2 (en) * 2015-10-29 2022-11-15 Juntendo Educational Foundation Method for producing pancreatic endocrine cells, and transdifferentiation agent
US11116777B2 (en) 2015-11-10 2021-09-14 City Of Hope Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) * 2015-12-31 2017-07-06 City Of Hope Methods for treating diabetes
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
GB2562406B (en) 2016-01-12 2020-09-02 Cedars Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
AU2017213795A1 (en) 2016-02-01 2018-08-16 Cedars-Sinai Medical Center Systems and methods for growth of intestinal cells in microfluidic devices
EP3420073B1 (en) * 2016-02-24 2023-11-08 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
US20190060371A1 (en) * 2016-03-02 2019-02-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgfbeta-inhibition
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
MA45329A (fr) 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
WO2017214465A1 (en) * 2016-06-09 2017-12-14 Georgetown University Process for continuous cell culture of islet cells
CA3027879A1 (en) * 2016-06-21 2017-12-28 Janssen Biotech, Inc. Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response
AU2017363142B2 (en) 2016-11-16 2024-05-30 Allele Biotechnology & Pharmaceuticals, Inc. Induction of hepatocytes by stem cell differentiation with RNA
IL266478B2 (en) 2016-11-16 2025-02-01 Allele Biotechnology & Pharmaceuticals Inc Induction of pancreatic beta cells through stem cell differentiation with RNA
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
KR101745297B1 (ko) 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2018176001A2 (en) 2017-03-24 2018-09-27 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
IL313825B2 (en) 2017-06-14 2025-07-01 Vertex Pharma Devices and methods for administering medications
US20210355448A1 (en) * 2017-06-26 2021-11-18 City Of Hope Methods of islet cell culture
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
JP2020527956A (ja) * 2017-07-21 2020-09-17 センマ・セラピューティクス・インコーポレーテッド 幹細胞由来の膵臓ベータ細胞の再凝集
CA2983845C (en) 2017-10-26 2024-01-30 University Of Copenhagen Generation of glucose-responsive beta cells
WO2019099725A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
WO2019169351A1 (en) * 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
US12161676B2 (en) 2018-03-23 2024-12-10 Cedars-Sinai Medical Center Methods of use of islet cells
US11981918B2 (en) 2018-04-06 2024-05-14 Cedars-Sinai Medical Center Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019195798A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
JP7543143B2 (ja) 2018-04-30 2024-09-02 シーダーズ－サイナイ メディカル センター 早期発症型孤発性パーキンソン病の分子シグネチャの診断及び薬物スクリーニング
JP2021522819A (ja) 2018-05-07 2021-09-02 プレジデント アンド フェローズ オブ ハーバード カレッジ インビトロベータ細胞分化に関連する細胞集団および遺伝子発現
WO2019217875A1 (en) 2018-05-11 2019-11-14 Cornell University Method of differentiation of human pluripotent stem cells to monohormonal cells
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2018439389A1 (en) * 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
WO2020061591A1 (en) 2018-09-21 2020-03-26 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
CN113166219A (zh) * 2018-09-28 2021-07-23 纪念斯隆-凯特琳癌症中心 干细胞衍生的人小神经胶质细胞、制备方法及使用方法
EP3868870B1 (en) * 2018-10-15 2025-12-03 Evia Life Sciences Inc. Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
US20220175848A1 (en) 2019-04-01 2022-06-09 The Broad Institute, Inc. Methods and compositions for cell therapy
EP3953451A1 (en) * 2019-04-08 2022-02-16 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
EP3972614A4 (en) 2019-05-21 2023-08-23 President and Fellows of Harvard College ENDOCRINE DIFFERENTIATION INDUCTION MOLECULE
KR102167257B1 (ko) * 2019-05-28 2020-10-19 부산대학교 산학협력단 토마티딘 처리를 통한 줄기세포의 성숙화된 심근세포로의 분화유도 촉진 방법
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
US12310830B2 (en) 2019-05-31 2025-05-27 W. L. Gore & Associates, Inc. Biocompatible membrane composite
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
WO2020247954A1 (en) * 2019-06-06 2020-12-10 President And Fellows Of Harvard College Compositions and methods for maturing stem cell-derived beta cells
WO2020264072A1 (en) 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
WO2021030424A1 (en) * 2019-08-13 2021-02-18 Semma Therapeutics, Inc. Pancreatic differentiation
US10740609B1 (en) 2019-08-30 2020-08-11 Numerica Corporation System and method for space object detection in daytime sky images
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
US11116798B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
WO2021072390A1 (en) * 2019-10-10 2021-04-15 The Regents Of The University Of Colorado, A Body Corporate Use of entpd3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
US20230014430A1 (en) * 2019-11-20 2023-01-19 Washington University Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
CN111269875B (zh) * 2020-03-24 2022-04-08 山东兴瑞生物科技有限公司 一种利用自体免疫细胞定向分化为胰岛细胞的方法
WO2021212044A1 (en) * 2020-04-16 2021-10-21 Washington University Methods and compositions for improving sc-beta cells or enhancing their utility
US12473537B2 (en) 2020-06-16 2025-11-18 The Broad Institute, Inc. Three-dimensional cell culture, devices, and use thereof
US20240271100A1 (en) * 2020-07-31 2024-08-15 Vertex Pharmaceuticals Incorporated In vitro differentiation of pancreatic endocrine cells
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells
CN112980771B (zh) * 2021-03-05 2023-12-19 贝康医学科技有限公司 一种制备胰腺beta细胞的方法及其应用
CN113046299B (zh) * 2021-03-19 2024-06-28 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的添加剂
CN112980774B (zh) * 2021-03-19 2022-04-01 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养方法
CN112961823B (zh) * 2021-03-19 2024-01-23 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养液
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
US20220403340A1 (en) * 2021-06-11 2022-12-22 Washington University Media for cryopreserved cells and methods of making and using same
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
JP2024531805A (ja) 2021-09-21 2024-08-29 学校法人沖縄科学技術大学院大学学園 ヒト脳オルガノイドを使用した、シヌクレイン病に対する薬物試験のプラットフォーム
JP2024540987A (ja) 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞
WO2023072170A1 (en) * 2021-10-28 2023-05-04 Sunshine Lake Pharma Co., Ltd. A METHOD FOR PROMOTING THE DIFFERENTIATION OF STEM CELLS INTO FUNCTIONALLY MATURE ISLET β CELLS AND USE THEREOF
JP2024542041A (ja) 2021-11-01 2024-11-13 バーテックス ファーマシューティカルズ インコーポレイテッド 幹細胞由来の膵臓島分化
CN118355109A (zh) * 2021-11-30 2024-07-16 杭州瑞普晨创科技有限公司 从多能干细胞生成功能性胰岛的方法
EP4473088A4 (en) * 2022-02-01 2026-01-14 Vertex Pharma CELL THERAPY FOR DIABETES
US12435312B2 (en) 2022-02-28 2025-10-07 Brown University Quantifying cell-derived changes in collagen synthesis, alignment, and mechanics in a 3D connective tissue model
US20230330264A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
US20250367240A1 (en) * 2022-06-03 2025-12-04 Cornell University Derivation of glucose-responsive insulin-secreting cells and organoids from human stomach cells and their use to treat diabetes
CN120187851A (zh) * 2022-10-28 2025-06-20 科罗拉多大学董事会法人 用于加速从多能干细胞产生胸腺细胞的组合物和方法
WO2024151541A1 (en) * 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
US20260218132A1 (en) * 2023-01-11 2026-07-30 Mayo Foundation For Medical Education And Research Methods and materials for generating stem cell-derived endocrine cell types
WO2024173283A1 (en) 2023-02-14 2024-08-22 Vertex Pharmaceuticals Incorporated Macroencapsulation devices including immunomodulatory compounds
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
IL325954A (en) * 2023-07-28 2026-03-01 Vertex Pharma Cell therapy for diabetes
CN117672411B (zh) * 2023-12-05 2024-05-14 首都医科大学附属北京世纪坛医院 一种中药成分的Hormesis效应研究方法及中药成分小檗碱的应用
WO2025168061A1 (en) * 2024-02-09 2025-08-14 Endocell Therapeutics Inc Methods for preparing endoderm stem cells and islets derived therefrom
WO2025235400A1 (en) * 2024-05-06 2025-11-13 Vertex Pharmaceuticals Incorporated Novel islet potency assay
CN121109289A (zh) * 2025-08-31 2025-12-12 瑞吉维思生物科技(上海)有限公司 高效维持胰岛β细胞身份的胰岛类器官及其制法和应用

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US130A (en) 1837-02-16 Improvement in metallic solutions for the preservation of timber
US6774A (en) 1849-10-09 Improved jointed center-board
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
DE1570610C3 (de) 1965-10-01 1974-08-01 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Poly-N-oxyden
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US5425764A (en) 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US7018419B2 (en) 1994-05-20 2006-03-28 Spielberg Theodore E Microporous encapsulated endocrine cell disks, biconcave disks and multidimpled chambers for hormonal replacement
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP0822834A4 (en) * 1995-04-07 2002-09-18 Einstein Coll Med RECOMBINANT (BETA) CELL AND ITS USE
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
JPH11508477A (ja) 1996-02-23 1999-07-27 サーシ・バイオメディカル・インコーポレーテッド 新規の人工膵臓
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
WO1999020740A2 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO2001051611A1 (en) 2000-01-14 2001-07-19 Bresagen Limited Cell production
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
EP1287116A2 (en) 2000-05-17 2003-03-05 Geron Corporation Neural progenitor cell populations
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6906810B2 (en) 2000-07-13 2005-06-14 Morgan Guaranty Trust Company Method and system for allowing an on-line user to selectively customize a document for printing in a single batch process
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ATE360063T1 (de) 2000-10-12 2007-05-15 Agency Science Tech & Res Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
CA2435826A1 (en) 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
WO2002092756A2 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
US7432104B2 (en) 2001-08-06 2008-10-07 Bresgen Inc. Methods for the culture of human embryonic stem cells on human feeder cells
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US20050053588A1 (en) 2001-10-18 2005-03-10 Li Yin Conversion of liver stem and progenitor cells to pancreatic functional cells
US20030077256A1 (en) 2001-10-19 2003-04-24 Paul Czernichow Pancreas regeneration using embryonic pancreatic cells
US7157278B2 (en) 2001-12-04 2007-01-02 Organogenesis, Inc. Cultured cells from pancreatic islets
CN1630716A (zh) 2001-12-07 2005-06-22 杰龙公司 人胚胎干细胞衍生的造血细胞
CA2469370C (en) 2001-12-07 2014-07-08 Macropore Biosurgery, Inc. Adipose-derived cell processing unit
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
WO2003102171A1 (en) 2002-05-28 2003-12-11 Becton, Dickinson And Company Expansion and transdifferentiation of human acinar cells
BR0311362A (pt) * 2002-05-28 2006-10-31 Novocell Inc métodos, composições e fatores de crescimento e de diferenciação para produzir células produtoras de insulina
AU2003302702B2 (en) 2002-12-05 2008-08-07 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
AU2003300522A1 (en) 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
US7172682B2 (en) 2003-01-24 2007-02-06 Rensselaer Polytechnic Institute Enzyme immobilization for electroosmotic flow
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US7084246B2 (en) 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
EP2722387B1 (en) 2003-12-23 2019-12-11 Viacyte, Inc. Definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US20090155218A1 (en) 2004-03-10 2009-06-18 Alberto Hayek Compositions and methods for growth of embryonic stem cells
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
JP2005278501A (ja) * 2004-03-30 2005-10-13 Asahi Kasei Corp 膵幹様細胞の分化誘導方法
KR20070029681A (ko) 2004-04-01 2007-03-14 위스콘신 얼럼나이 리서어치 화운데이션 줄기 세포의 내배엽 및 이자 혈통으로의 분화
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
AU2005271723B2 (en) 2004-07-13 2010-12-16 Asterias Biotherapeutics, Inc. Medium for growing human embryonic stem cells
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
AU2006210955A1 (en) 2005-01-31 2006-08-10 Es Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
DK1864132T3 (da) 2005-03-31 2012-07-16 Stemnion Inc Fra amnion stammende cellesammensætninger, fremgangsmåder til fremstilling deraf og anvendelser deraf
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
KR20130099253A (ko) 2005-06-22 2013-09-05 제론 코포레이션 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화
EP1906972B1 (en) 2005-07-19 2013-09-11 The University of Tennessee Research Foundation LPA2 receptor agonist for treating diarrhea
ES2687233T3 (es) 2005-10-27 2018-10-24 Viacyte, Inc. Endodermo de intestino proximal dorsal y ventral que expresa PDX-1
CN101330914A (zh) 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
WO2007075807A2 (en) 2005-12-20 2007-07-05 Es Cell International Pte Ltd. Methods for the directed differentiation of embryonic stem cell
AU2007207434B2 (en) 2006-01-20 2012-04-05 Reneuron, Inc. Method of improving cell proliferation of pancreatic progenitor cells in a pancreatic cell culture
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
EP1989297B1 (en) 2006-02-13 2015-03-25 The Board of Trustees of The Leland Stanford Junior University Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
EP2420565B1 (en) 2006-02-23 2017-08-30 ViaCyte, Inc. Compositions and methods useful for culturing differentiable cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
NZ571427A (en) 2006-03-02 2012-07-27 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007109673A2 (en) 2006-03-20 2007-09-27 Stanford University Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
ES2725601T3 (es) 2006-04-28 2019-09-25 Lifescan Inc Diferenciación de células madre embriónicas humanas
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
WO2007149182A2 (en) 2006-06-19 2007-12-27 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
WO2008013664A2 (en) 2006-07-26 2008-01-31 Cythera, Inc. Methods of producing pancreatic hormones
CA2662209C (en) 2006-08-29 2015-02-17 The University Of Akron Implantable devices for producing insulin
WO2008083331A2 (en) * 2006-12-29 2008-07-10 The Regents Of The University Of Colorado Diagnostic and therapeutic target for autoimmune diseases and uses thereof
JP5636192B2 (ja) * 2007-02-21 2014-12-03 エス・ア・エール・エル アンドセルＳａｒｌ Ｅｎｄｏｃｅｌｌｓ 糖尿病の診断のためのヒト膵臓β細胞株
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009012428A2 (en) 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
JP5374370B2 (ja) 2007-08-09 2013-12-25 株式会社ヤクルト本社 新規γセクレターゼ阻害剤
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
SG154367A1 (en) * 2008-01-31 2009-08-28 Es Cell Int Pte Ltd Method of differentiating stem cells
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
DK2283117T3 (da) 2008-04-21 2014-01-20 Viacyte Inc Fremgangsmåde til oprensning af pancreatiske endodermceller afledt fra humane embryoniske stamceller
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US9683215B2 (en) * 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP2012507289A (ja) * 2008-10-31 2012-03-29 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
EP2346988B1 (en) * 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
CA2744227C (en) 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8507274B2 (en) 2009-02-06 2013-08-13 President And Fellows Of Harvard College Compositions and methods for promoting the generation of definitive endoderm
US20100267731A1 (en) 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
ES2849181T3 (es) * 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
WO2010129294A2 (en) 2009-04-27 2010-11-11 Schulz Thomas C Small molecules supporting pluripotent cell growth and methods thereof
WO2010135639A2 (en) * 2009-05-21 2010-11-25 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
EP2456858B1 (en) * 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
RU2540016C2 (ru) 2009-07-20 2015-01-27 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека
PH12012500818A1 (en) * 2009-10-29 2019-11-29 Janssen Biotech Inc Pluripotent stem cells
DK2516625T3 (da) 2009-12-23 2024-09-09 Janssen Biotech Inc Differentiering af humane embryonale stamceller
EP2505639B1 (en) * 2009-12-29 2018-09-19 Takeda Pharmaceutical Company Limited Method for manufacturing pancreatic-hormone-producing cells
AU2011223900A1 (en) * 2010-03-01 2012-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
JP2013524836A (ja) 2010-04-25 2013-06-20 マウント・シナイ・スクール・オブ・メディスン 多能性細胞からの前部前腸内胚葉の生成
AU2011250912A1 (en) * 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2011290123B2 (en) * 2010-08-09 2016-11-10 Takeda Pharmaceutical Company Limited Method of producing pancreatic hormone-producing cells
CN103052393B (zh) * 2010-08-12 2017-11-14 詹森生物科技公司 用胰腺内分泌前体细胞治疗糖尿病
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2012044486A1 (en) 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US20120270890A1 (en) * 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
MX364602B (es) 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
US20130071931A1 (en) 2011-08-02 2013-03-21 National Cancer Center Process for hepatic differentiation from induced hepatic stem cells, and induced hepatic progenitor cells differentiated thereby
US20140243374A1 (en) 2011-10-04 2014-08-28 The Brigham And Women's Hospital, Inc. Novel Sulfonamides
ES2634457T3 (es) * 2011-10-18 2017-09-27 Univercell Biosolutions Producción de una línea de células beta humanas a partir de un páncreas postnatal temprano
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
RU2705001C2 (ru) * 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
US20140162359A1 (en) 2012-05-07 2014-06-12 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Pancreatic Endoderm
CN104395323B (zh) 2012-05-08 2017-08-01 默沙东公司 可透过性糖苷酶抑制剂及其用途
WO2013166654A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
CN104334719B (zh) 2012-06-08 2018-02-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
RU2015100900A (ru) 2012-06-14 2016-08-10 Янссен Байотек, Инк. Обработка плюрипотентных клеток
EP2893000B1 (en) 2012-09-03 2019-04-10 Novo Nordisk A/S Generation of pancreatic endoderm from pluripotent stem cells using small molecules
KR102084561B1 (ko) 2012-12-31 2020-03-04 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양
MX2015008578A (es) * 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
DK2938722T3 (da) 2012-12-31 2022-02-14 Janssen Biotech Inc Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US20140287944A1 (en) 2013-02-26 2014-09-25 President And Fellows Of Harvard College Markers for functionally mature beta-cells and methods of using the same
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
US20140329704A1 (en) 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
AU2014278178B2 (en) 2013-06-11 2021-01-21 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
DK3039122T3 (da) 2013-08-30 2019-09-30 Novo Nordisk As Generering af endokrine progenitorceller fra humane pluripotente stamceller under anvendelse af små molekyler
SG11201609473XA (en) * 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
WO2016100925A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
US9974784B2 (en) 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
EP3420073B1 (en) 2016-02-24 2023-11-08 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093654A (ja) * 2013-06-11 2023-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＳＣ－β細胞及び組成物並びにその生成方法
JP7766641B2 (ja) 2013-06-11 2025-11-10 プレジデント アンド フェローズ オブ ハーバード カレッジ ＳＣ－β細胞及び組成物並びにその生成方法

Also Published As

Publication number Publication date
KR20160099079A (ko) 2016-08-19
KR20210008926A (ko) 2021-01-25
RU2016100433A (ru) 2017-07-17
KR102390167B1 (ko) 2022-04-25
US20150218522A1 (en) 2015-08-06
AU2026202516A1 (en) 2026-04-23
US20220162562A1 (en) 2022-05-26
US11827905B2 (en) 2023-11-28
PH12015502767A1 (en) 2016-03-21
GB2549822B (en) 2018-05-02
DE112014002780B4 (de) 2025-05-22
CN112226402A (zh) 2021-01-15
GB2531952A (en) 2016-05-04
KR20200143750A (ko) 2020-12-24
KR20220051442A (ko) 2022-04-26
US20250019661A1 (en) 2025-01-16
JP2020108394A (ja) 2020-07-16
KR20240014630A (ko) 2024-02-01
US10655106B2 (en) 2020-05-19
RU2019108582A (ru) 2019-07-05
KR102631225B1 (ko) 2024-01-31
EP3008168A2 (en) 2016-04-20
AU2020289721B2 (en) 2023-09-14
US11162078B2 (en) 2021-11-02
JP2026082908A (ja) 2026-05-19
GB2531952C (en) 2019-10-09
US20220396775A1 (en) 2022-12-15
AU2023229504A1 (en) 2023-09-28
RU2016100219A (ru) 2017-07-17
BR112015030946A2 (pt) 2017-07-25
AU2014284677A1 (en) 2016-02-25
EP4461806A2 (en) 2024-11-13
CN110551678A (zh) 2019-12-10
SG10201710218RA (en) 2018-01-30
JP2025063288A (ja) 2025-04-15
DK3008168T3 (da) 2020-05-04
AU2023237028A1 (en) 2023-10-12
EP3008170A1 (en) 2016-04-20
WO2015002724A4 (en) 2015-03-26
AU2014284677B2 (en) 2020-03-12
DE202014011287U1 (de) 2019-02-06
RU2019108582A3 (enExample) 2021-08-04
KR102640729B1 (ko) 2024-02-27
US20170029778A1 (en) 2017-02-02
JP6893527B2 (ja) 2021-06-23
CN106414718A (zh) 2017-02-15
AU2020203127C1 (en) 2023-12-21
GB2531952B (en) 2017-02-08
KR20220106230A (ko) 2022-07-28
KR102341674B1 (ko) 2021-12-22
JP2016531087A (ja) 2016-10-06
US10030229B2 (en) 2018-07-24
EP3008170A4 (en) 2016-11-09
AU2023229504B2 (en) 2026-08-13
MX2015017103A (es) 2016-11-07
GB2549822A (en) 2017-11-01
KR102232650B1 (ko) 2021-03-29
KR102423106B1 (ko) 2022-07-21
AU2020289721A1 (en) 2021-01-21
US20240101963A1 (en) 2024-03-28
EP3569694A1 (en) 2019-11-20
WO2015002724A2 (en) 2015-01-08
AU2020203127B2 (en) 2023-06-22
KR102523912B1 (ko) 2023-04-21
KR102201638B1 (ko) 2021-01-13
SG11201510177WA (en) 2016-01-28
KR20230054767A (ko) 2023-04-25
US20250043247A1 (en) 2025-02-06
CN105579577A (zh) 2016-05-11
BR112015030972A8 (pt) 2020-01-28
GB201622354D0 (en) 2017-02-15
JP2019141072A (ja) 2019-08-29
GB201803318D0 (en) 2018-04-18
US11104883B2 (en) 2021-08-31
KR20160034892A (ko) 2016-03-30
KR20210156337A (ko) 2021-12-24
WO2015002724A3 (en) 2015-02-26
WO2014201167A4 (en) 2015-01-29
BR112015030946A8 (pt) 2020-01-28
US12054745B2 (en) 2024-08-06
KR102773841B1 (ko) 2025-02-27
US20190017031A1 (en) 2019-01-17
AU2023237028B2 (en) 2026-01-08
US11078463B2 (en) 2021-08-03
JP2016532436A (ja) 2016-10-20
CN121427797A (zh) 2026-01-30
US20240124847A1 (en) 2024-04-18
US20210079355A1 (en) 2021-03-18
US20150240212A1 (en) 2015-08-27
KR20230135180A (ko) 2023-09-22
MX2019003616A (es) 2019-08-01
US20200347358A1 (en) 2020-11-05
CN120796168A (zh) 2025-10-17
CA2915091A1 (en) 2014-12-18
GB2557508A9 (en) 2018-09-05
CN110551678B (zh) 2024-02-20
EP3008168A4 (en) 2017-05-31
RU2692595C2 (ru) 2019-06-25
KR20210034688A (ko) 2021-03-30
US20190040362A1 (en) 2019-02-07
AU2014278178B2 (en) 2021-01-21
CA3311831A1 (en) 2026-06-21
JP2023093654A (ja) 2023-07-04
JP6514689B2 (ja) 2019-05-15
EP4461806A3 (en) 2025-02-12
GB2557508A (en) 2018-06-20
KR102361924B1 (ko) 2022-02-14
GB201521857D0 (en) 2016-01-27
RU2016100219A3 (enExample) 2018-03-30
CA2915088A1 (en) 2015-01-08
AU2014278178A1 (en) 2016-01-28
US20200385681A1 (en) 2020-12-10
BR112015030972A2 (pt) 2017-07-25
JP2024054254A (ja) 2024-04-16
DE112014002780T5 (de) 2016-06-23
US20190169575A1 (en) 2019-06-06
KR102205234B1 (ko) 2021-01-20
KR20220025151A (ko) 2022-03-03
JP2021121223A (ja) 2021-08-26
WO2014201167A1 (en) 2014-12-18
JP7766641B2 (ja) 2025-11-10
SG11201510176VA (en) 2016-03-30
US12049646B2 (en) 2024-07-30
JP7354026B2 (ja) 2023-10-02
AU2020203127A1 (en) 2020-06-04
HK1257187B (zh) 2020-06-12
GB2557508B (en) 2018-11-07
KR102580225B1 (ko) 2023-09-20
US20230076529A1 (en) 2023-03-09
EP3008168B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
US12049646B2 (en) SC-beta cells and compositions and methods for generating the same
RU2772585C2 (ru) КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160513

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200313

R150 Certificate of patent or registration of utility model

Ref document number: 6677634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250